Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.39 |
| ▸ | CA1 | P00915 | 12/20 | 0.39 |
| ▸ | CA12 | O43570 | 11/20 | 0.39 |
| ▸ | CA9 | Q16790 | 11/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.39 |
| ▸ | CA4 | P22748 | 9/20 | 0.39 |
| ▸ | CA6 | P23280 | 7/20 | 0.39 |
| ▸ | CA5A | P35218 | 7/20 | 0.39 |
| ▸ | CA7 | P43166 | 7/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927671 | 0.75 | CA2 (0.41) | CA2CA1CA12CA9CA14 | |
| SCHEMBL7550351 | 0.75 | CA2 (0.39) | CA2CA1CA12CA9CA14 | |
| SCHEMBL4977235 | 0.75 | CA2 (0.41) | CA2CA1CA12CA9CA14 | |
| SCHEMBL20564260 | 0.73 | PTGS2 (0.40) | CA2CA1CA12CA9CA14 | |
| SCHEMBL2068726 | 0.73 | NPC1 (0.43) | CA2CA1CA12CA9CA6 | |
| SCHEMBL1927963 | 0.73 | GAA (0.41) | CA2CA1CA12CA9CA14 | |
| SCHEMBL10616070 | 0.72 | NSD2 (0.46) | CYP2C9MEN1MAPTKMT2AKDM4E | |
| SCHEMBL5655444 | 0.70 | CA2 (0.42) | CA2CA1CA12CA9CA14 | |
| SCHEMBL23569219 | 0.69 | CA2 (0.35) | CA2CA1CA12CA9CA14 | |
| SCHEMBL5652749 | 0.69 | CA2 (0.37) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| CN-101945859-A | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-1448545-A1 | NF-KB INHIBITORS | SmithKline Beecham Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1324759-A4 | NF-G(K)B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040024047-A1 | Nf-kb inhibitors | SMITHKLINE BEECHMAN CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1324759-A2 | NF-G(K)B INHIBITORS | SmithKline Beecham Corporation (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003029242-A1 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002030353-A2 | NF-λB INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-0165753-B1 | HERBICIDAL THIOPHENESULFONAMIDES AND PYRIDINESULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| US-4723988-A | PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-09 | — | — | US | disclosed |
| US-4684393-A | PLATN GROWTH REGULATORS | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0165753-A2 | Herbicidal thiophenesulfonamides and pyridinesulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | CA2 2457/4885CA1 3319/4885CA12 4459/4885 |
| US-20040024047-A1 | Nf-kb inhibitors | NFKBIA, IKBKB, IKBKG | CA2 4618/4885CA1 4840/4885CA12 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.